VistaGen Therapeutics
VTGN
34 hedge funds and large institutions have $15.7M invested in VistaGen Therapeutics in 2023 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 11 increasing their positions, 7 reducing their positions, and 12 closing their positions.
767% more capital invested
Capital invested by funds: $1.82M → $15.7M (+$13.9M)
494% more call options, than puts
Call options by funds: $4.96M | Put options by funds: $835K
57% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 7
19.74% more ownership
Funds ownership: 12.35% → 32.09% (+20%)
3% more funds holding
Funds holding: 33 → 34 (+1)
8% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
+$6.99M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
+$1.02M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
+$615K |
| 4 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$444K |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$444K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$675K |
| 2 |
Millennium Management
New York
|
-$374K |
| 3 |
Goldman Sachs
New York
|
-$107K |
| 4 |
YIH
Y-Intercept (HK)
Hong Kong
|
-$89.2K |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$77.3K |
VTGN Hedge Fund Activity: Q3 2023 in Review
34 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q3 2023, worth a combined $15.7M — up 767% from $1.82M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new VTGN positions and 12 closed out — a net gain of 1 holder — while 11 added to existing stakes and 7 trimmed.
The largest buyer was Commodore Capital, opening a new position worth an estimated $6.99M. The largest seller was GSA Capital Partners, cutting an estimated $675K.
- 34 institutional investors held VistaGen Therapeutics (VTGN) as of Q3 2023, up from 33 in Q2 2023.
- Funds reported $15.7M of VistaGen Therapeutics stock for Q3 2023, up 767% quarter-over-quarter.
- 13 funds opened new VistaGen Therapeutics positions in Q3 2023 and 12 closed out, a net change of +1 holder.
- The largest VistaGen Therapeutics buyer in Q3 2023 was Commodore Capital, an estimated $6.99M added.
- The largest VistaGen Therapeutics seller in Q3 2023 was GSA Capital Partners, an estimated $675K sold.
Based on aggregated 13F filings for Q3 2023.